The aims of this study were: (i) to analyse the load-velocity relationship in the bilateral leg-press exercise in female breast cancer survivors, (ii) to assess whether mean velocity (MV) or peak velocity (PV) show stronger relationship with the relative load, and (iii) to examine whether linear (LA) or polynomic (PA) adjustment predict the velocities associated with each %1RM with greater precision. Twenty-two female breast cancer survivors (age: 50.2 ± 10.8 years, weight: 69.6 ± 15.2 kg, height: 160.51 ± 5.25 cm) completed an incremental load test until 1RM in the bilateral leg-press exercise. The MV and the PV of the concentric phase were measured in each repetition using a linear velocity transducer, and were analysed by regression models using LA and PA. A very close relationship of MV (= 0.924; < 0.0001; SEE = 0.08ms by LA, and ² = 0.952; < 0.0001; SEE = 0.063 ms by PA) and PV (² = 0.928; < 0.0001; SEE = 0.119 ms by LA and ² = 0.941; < 0.0001; SEE = 0.108 ms by PA) with %1RM were observed. The MV of 1RM was 0.24 ± 0.03 m·s, whereas the PV at 1RM was 0.60 ± 0.10 ms. A comprehensive analysis of the bilateral leg-press load-velocity relationship in breast cancer survivors is presented. The results suggest that MV is the most recommendable velocity variable to prescribe the relative load during resistance training, and that the PA presents better accuracy to predict velocities associated with each %1RM, although LA is sufficiently valid to use this model as an alternative to the quadratic model. The implications for resistance training in breast cancer are discussed. The load-velocity relationship in the bilateral leg-press exercise was described in female breast cancer survivors.The mean velocity is the most recommendable velocity variable to prescribe the relative load during resistance training in this population.The polynomial adjustment presents a better accuracy to predict velocities associated with each %1RM, although the linear adjustment is sufficiently valid as an alternative.This study will likely contribute to improving exercise prescription and monitoring in breast cancer survivors.

Download full-text PDF

Source
http://dx.doi.org/10.1080/17461391.2021.1965220DOI Listing

Publication Analysis

Top Keywords

breast cancer
12
cancer survivors
12
leg-press exercise
12
load-velocity relationship
8
bilateral leg-press
8
female breast
8
improving resistance
4
resistance training
4
training prescription
4
prescription load-velocity
4

Similar Publications

Background: Thyroid Hormones (THs) critically impact human cancer. Although endowed with both tumor-promoting and inhibiting effects in different cancer types, excess of THs has been linked to enhanced tumor growth and progression. Breast cancer depends on the interaction between bulk tumor cells and the surrounding microenvironment in which mesenchymal stem cells (MSCs) exert powerful pro-tumorigenic activities.

View Article and Find Full Text PDF

The Role of NF-κB/MIR155HG in Regulating the Stemness and Radioresistance in Breast Cancer Stem Cells.

Front Biosci (Landmark Ed)

January 2025

Department of Chemoradiotherapy, Ningbo No 2 Hospital, 315000 Ningbo, Zhejiang, China.

Background: Breast cancer stem cells (BCSCs) are instrumental in treatment resistance, recurrence, and metastasis. The development of breast cancer and radiation sensitivity is intimately pertinent to long non-coding RNA (lncRNA). This work is formulated to investigate how the lncRNA affects the stemness and radioresistance of BCSCs.

View Article and Find Full Text PDF

Update on the Progress of Musashi-2 in Malignant Tumors.

Front Biosci (Landmark Ed)

January 2025

Department of Hepatobiliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 030032 Taiyuan, Shanxi, China.

Since the discovery of the Musashi (MSI) protein, its ability to affect the mitosis of Drosophila progenitor cells has garnered significant interest among scientists. In the following 20 years, it has lived up to expectations. A substantial body of evidence has demonstrated that it is closely related to the development, metastasis, migration, and drug resistance of malignant tumors.

View Article and Find Full Text PDF

Tryptophan catabolism is a central pathway in many cancers, serving to sustain an immunosuppressive microenvironment. The key enzymes involved in this tryptophan metabolism such as indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are reported as promising novel targets in cancer immunotherapy. IDO1 and TDO overexpression in TNBC cells promote resistance to cell death, proliferation, invasion, and metastasis.

View Article and Find Full Text PDF

Socio-economic inequalities in second primary cancer incidence: A competing risks analysis of women with breast cancer in England between 2000 and 2018.

Int J Cancer

January 2025

Inequalities in Cancer Outcomes Network (ICON) group, Department of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.

We aimed to investigate socio-economic inequalities in second primary cancer (SPC) incidence among breast cancer survivors. Using Data from cancer registries in England, we included all women diagnosed with a first primary breast cancer (PBC) between 2000 and 2018 and aged between 18 and 99 years and followed them up from 6 months after the PBC diagnosis until a SPC event, death, or right censoring, whichever came first. We used flexible parametric survival models adjusting for age and year of PBC diagnosis, ethnicity, PBC tumour stage, comorbidity, and PBC treatments to model the cause-specific hazards of SPC incidence and death according to income deprivation, and then estimated standardised cumulative incidences of SPC by deprivation, taking death as the competing event.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!